GB697351A - Improved process for the manufacture of nerve sedatives - Google Patents

Improved process for the manufacture of nerve sedatives

Info

Publication number
GB697351A
GB697351A GB6474/51A GB647451A GB697351A GB 697351 A GB697351 A GB 697351A GB 6474/51 A GB6474/51 A GB 6474/51A GB 647451 A GB647451 A GB 647451A GB 697351 A GB697351 A GB 697351A
Authority
GB
United Kingdom
Prior art keywords
sedative
tissues
dispersion
saline solution
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB6474/51A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MASUICHI TAKINO
Original Assignee
MASUICHI TAKINO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MASUICHI TAKINO filed Critical MASUICHI TAKINO
Publication of GB697351A publication Critical patent/GB697351A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A sedative for all the peripheral nerves is prepared by inoculating or infecting organs or tissues of animals such as cows or rabbits with cowpox, removing the organs or tissues 3 to 10 days after inoculation or infection, dispersing them in an aqueous medium, completely removing protein ingredients from the dispersion, and recovering the sedative, which contains no virus protein or lipoid, from the liquid so obtained. The aqueous medium is physiological saline solution, water, glycerin water, or a mixture thereof, containing carbolic acid. In the example, a portion of the testicles or skins of animals is removed 4-5 days after inoculation, well-ground and dispersed in a mixture of physiological saline solution, glycerin and carbolic acid. The dispersion is alternatively frozen at -5 to -10 DEG C. and thawed at 15-20 DEG C., allowed to stand, the supernatant liquid decanted and proteins removed in stages by (a) heating to 100 DEG C. for 1 hour (b) adjusting pH to 5 by the addition of hydrochloric acid and (c) filtering through asbestos treated with sodium silicate and magnesium sulphate. The filtrate from (c) is treated with kaolin at pH 4.5-4.7. The absorbate containing the virus and sedative is eluted with N/24-N/26 aqueous ammonia and filtered. The filtrate is adjusted to pH 7.4-7.8 with N/1 acetic acid, concentrated in vacuo, and the sedative precipitated by the addition of a water-miscible organic solvent e.g. acetone or ethylalcohol. The effective material can be isolated by cataphoresis of the clear liquid obtained after heating and freezing a dispersion of the tissues in saline solution. Active material may also be isolated from urine of infected animals or from a cowpox inoculated hatching egg.
GB6474/51A 1951-01-16 1951-03-19 Improved process for the manufacture of nerve sedatives Expired GB697351A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP697351X 1951-01-16

Publications (1)

Publication Number Publication Date
GB697351A true GB697351A (en) 1953-09-23

Family

ID=13411354

Family Applications (1)

Application Number Title Priority Date Filing Date
GB6474/51A Expired GB697351A (en) 1951-01-16 1951-03-19 Improved process for the manufacture of nerve sedatives

Country Status (1)

Country Link
GB (1) GB697351A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534509A (en) * 1993-03-19 1996-07-09 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition regulating function of a living body
US5560935A (en) * 1993-09-28 1996-10-01 Nippon Zoki Pharmaceutical Co., Ltd. Physiologically active substances extracted from activated tissues
US5599683A (en) * 1993-08-06 1997-02-04 Nippon Zoki Pharmaceutical Co., Ltd. Method for measuring production activity of test substance towards FXIIa
US5648228A (en) * 1993-08-06 1997-07-15 Nippon Zoki Pharmaceutical Co., Ltd. Measuring activity toward production of activated blood coagulation factor XII, plasma kallikrein or bradykinin using reconstituted kallikrein-kinin system
US6051613A (en) * 1997-01-08 2000-04-18 Nippon Zoki Pharmaceutical Co., Ltd. Nitrogen monoxide production suppressor
US6165515A (en) * 1997-09-12 2000-12-26 Nippon Zoki Pharmaceutical Co., Ltd. Method for treatment of osteoporosis
US6365192B1 (en) 1999-04-15 2002-04-02 Nippon Zoki Pharmaceutical Co., Ltd. Bioactivating substance
US6541041B1 (en) 1997-11-28 2003-04-01 Nippon Zoki Pharmaceutical Co., Ltd. Crude drug extracts, and methods for making and standardizing same
US6726932B2 (en) 2000-02-18 2004-04-27 Nippon Zoki Pharmaceutical Co., Ltd. Fatty acid-containing composition
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
US8293280B2 (en) 2004-12-17 2012-10-23 Nippon Zoki Pharmaceutical Co., Ltd. Method for treatment of HIV infection
US8568789B2 (en) 2004-12-01 2013-10-29 Nippon Zoki Pharmaceutical Co., Ltd. Dried product and a process for manufacturing the product
US9884077B2 (en) 2013-04-30 2018-02-06 Nippon Zoki Pharmaceutical Co., Ltd. Extract and preparation containing said extract

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658896A (en) * 1993-03-19 1997-08-19 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition regulating function of a living body
US5807951A (en) * 1993-03-19 1998-09-15 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition regulating function of a living body
US5534509A (en) * 1993-03-19 1996-07-09 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition regulating function of a living body
US5599683A (en) * 1993-08-06 1997-02-04 Nippon Zoki Pharmaceutical Co., Ltd. Method for measuring production activity of test substance towards FXIIa
US5648228A (en) * 1993-08-06 1997-07-15 Nippon Zoki Pharmaceutical Co., Ltd. Measuring activity toward production of activated blood coagulation factor XII, plasma kallikrein or bradykinin using reconstituted kallikrein-kinin system
US5560935A (en) * 1993-09-28 1996-10-01 Nippon Zoki Pharmaceutical Co., Ltd. Physiologically active substances extracted from activated tissues
US6051613A (en) * 1997-01-08 2000-04-18 Nippon Zoki Pharmaceutical Co., Ltd. Nitrogen monoxide production suppressor
US6165515A (en) * 1997-09-12 2000-12-26 Nippon Zoki Pharmaceutical Co., Ltd. Method for treatment of osteoporosis
US6576241B2 (en) 1997-11-28 2003-06-10 Nippon Zoki Pharmaceutical Co., Ltd. Crude drug extracts, and methods for making and standardizing same
US6541041B1 (en) 1997-11-28 2003-04-01 Nippon Zoki Pharmaceutical Co., Ltd. Crude drug extracts, and methods for making and standardizing same
US6365192B1 (en) 1999-04-15 2002-04-02 Nippon Zoki Pharmaceutical Co., Ltd. Bioactivating substance
US6726932B2 (en) 2000-02-18 2004-04-27 Nippon Zoki Pharmaceutical Co., Ltd. Fatty acid-containing composition
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
US8568789B2 (en) 2004-12-01 2013-10-29 Nippon Zoki Pharmaceutical Co., Ltd. Dried product and a process for manufacturing the product
US8293280B2 (en) 2004-12-17 2012-10-23 Nippon Zoki Pharmaceutical Co., Ltd. Method for treatment of HIV infection
US9884077B2 (en) 2013-04-30 2018-02-06 Nippon Zoki Pharmaceutical Co., Ltd. Extract and preparation containing said extract

Similar Documents

Publication Publication Date Title
Vogel et al. Adsorption-hemagglutination test for influenza virus in monkey kidney tissue culture
US3396081A (en) Hyaluronic acid preparation and method of producing same
GB697351A (en) Improved process for the manufacture of nerve sedatives
Underdahl et al. Cultivation in tissue-culture of cytopathogenic agent from bovine mucosal disease.
Rogers et al. The physiology of the second ecdysis of parasitic nematodes
Bremner et al. Acetylcholinesterase secretion by parasitic nematodes—III. Oesophagostomum spp.
Carrel Essential characteristics of a malignant cell
Lack Spherule Formation and Endosporulation of the Fungus Coccidioides in vitro.
Beckett et al. Some histochemical observations on human dystrophic muscle
Findlay A note on the cultivation of the virus of fowl-pox
Howitt Poliomyelitis Virus. Results of Treating with Certain Chemicals and with Heat.
Beadle et al. Carbon dioxide narcosis
DE2050945A1 (en) Process for growing viable Staphylococcus bacteria to produce an antiviral substance
Nelson The stability of variola virus propagated in embryonated eggs
Cox et al. Cultivation of vesicular stomatitis virus
Vogel et al. The action of miracil in Schistosoma japonicum infections in laboratory animals
Rao et al. ANIMAL. RH|| NOSPORIDIOSIS| N|| ND| A WITH (CASE REPORTS
Frenkel et al. Cultivation of foot-and-mouth disease virus in explanted epithelial tissue of the bovine rumen
US4085206A (en) Composition for treatment of infectious diseases in animals
Banting Resistance to experimental cancer
Veerkamp et al. Mode of action of beryllium on alkaline phosphatase
DE1030516B (en) Nutrient soil for virus breeding
Ide et al. Studies with a rhinovirus of bovine origin: I. growth in vitro of strain RS 3x
Verlinde et al. Studies on haemagglutination by the EMC-MM-Columbia SK-group of viruses: IV. Experiments with egg-adapted virus
DE2524822C3 (en) Neutral protease, process for its preparation and its use for disrupting animal tissue and for suspension cell culture